Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM

A vaccine consisting of irradiated allogeneic breast cancer cells, derived from the breast cancer cell line SV-BR-1 that are transfected with the immunostimulant granulocyte-macrophage colony-stimulating factor (GM-CSF; CSF2) gene, with potential immunostimulating and antineoplastic activities. Upon intradermal administration of the allogeneic GM-CSF-secreting breast cancer vaccine SV-BR-1-GM, the genetically-modified cells secrete GM-CSF. This potentiates a tumor-specific cytotoxic T-lymphocyte (CTL) immune response against breast cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Breast Cancer Vaccine SV-BR-1-GM
GM-CSF gene-transfected breast cancer vaccine SV-BR-1-GM
SV-BR-1 breast cancer cell line vaccine
SV-BR-1-GM
SV-BR-1-GM vaccine
US brand name:Bria-IMT
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search